Oxford Biomedica Appoints
Laurence Espinasse as Non-Executive Director
Oxford, UK - 25 July
2024: Oxford Biomedica plc (LSE:OXB)
("Oxford Biomedica", "OXB" or "the Company"), a quality and
innovation-led cell and gene therapy CDMO, today announces the
appointment of Laurence Espinasse as a Non-Executive Director,
effective as of 24 July 2024.
Ms. Espinasse brings more than two
decades of experience across the legal and healthcare sectors and
since 2021 has served as the General Counsel and Compliance Officer
at Institut Mérieux SA ("Institut Mérieux"). Following the
acquisition of ABL Europe (since
renamed Oxford Biomedica (France)) in January 2024, Institut
Mérieux is now a major shareholder in Oxford Biomedica, owning more
than 10 percent of the Company's ordinary shares.
Prior to her current role at
Institut Mérieux, Ms. Espinasse was a Partner and Head of the
Business Law Department at MDL Société d'Avocats. Before that, she
practiced business law at EY. She obtained her professional
lawyer's certificate from the École des Avocats Centre Sud in
Montpellier, France.
Dr. Roch Doliveux, Chair of
Oxford Biomedica, commented: "On behalf of the Board, I am
delighted to welcome Laurence Espinasse as Non-Executive Director.
Her vast legal experience will be a strong asset for the Company as
we look to build on significant commercial momentum
and capitalise on the fast-growing
cell and gene therapy sector. We look
forward to her support and advice in driving OXB's continued
success."
Laurence Espinasse, incoming
Board Member at Oxford Biomedica,
added: "Following the acquisition
of ABL Europe, I am honoured to be joining Oxford
Biomedica's Board of Directors. Institut Mérieux's
significant investment reflects our confidence in Oxford
Biomedica's potential. I look forward to working closely with the
Board to drive the next phase of growth as a world-leading cell and
gene therapy CDMO."
Relevant disclosures
Ms. Espinasse previously served as a director at Transgene SA, from May 2022
to May 2023. There are no additional disclosures required to be
made in accordance with LR 9.6.13R.
-Ends-
Enquiries:
Oxford Biomedica plc:
Sophia Bolhassan, Head of Investor
Relations - T: +44 (0) 1865 509 737 / E: ir@oxb.com
ICR
Consilium:
T: +44 (0)20 3709 5700 /
E: oxfordbiomedica@icrhealthcare.com
Mary-Jane Elliott / Angela Gray /
Davide Salvi
About Oxford Biomedica
Oxford Biomedica (LSE: OXB) is a
quality and innovation-led contract development and manufacturing
organisation (CDMO) in cell and gene therapy with a mission to
enable its clients to deliver life changing therapies to patients
around the world.
One of the original pioneers in cell
and gene therapy, OXB has more than 25 years of experience in viral
vectors; the driving force behind the majority of cell and gene
therapies. OXB collaborates with some of the world's most
innovative pharmaceutical and biotechnology companies, providing
viral vector development and manufacturing expertise in lentivirus,
adeno-associated virus (AAV), adenovirus, and other viral vector
types. Oxford Biomedica's world-class capabilities span from
early-stage development to commercialisation. These capabilities
are supported by robust quality-assurance systems, analytical
methods and depth of regulatory expertise.
Oxford Biomedica, a FTSE4Good
constituent, is headquartered in Oxford, UK. It has bioprocessing and manufacturing facilities across
Oxfordshire, UK, Lyon and Strasbourg, France, and near Boston, MA,
US. Learn more at www.oxb.com, and follow us
on LinkedIn and YouTube.